Literature DB >> 1892761

The roles of age and sex in the prognosis of chronic leukaemias. A study of 373 cases.

B Jaksić1, B Vitale, E Hauptmann, A Planinc-Peraica, S Ostojic, R Kusec.   

Abstract

The roles of age and sex and their relationship to other prognostic factors were studied in 117 chronic myeloid leukaemia (CML) and in 256 chronic lymphocytic leukaemia (CLL) patients. Survival in CML was not related either to age at diagnosis or to sex. In contrast, the CLL patients classified into four age strata (less than 50, 50-59, 60-69, greater than 70 years) had an expected median survival (EMS) of 142, 101, 85 and 33 months respectively (chi 2 for heterogeneity = 35.59, P less than 0.0005; chi 2 for trend = 25.09, P less than 0.0005). Prognostic power was independent of sex, Rai stages, total tumour mass score (TTM), TTM distribution pattern, anaemia, thrombocytopenia, serum immunoglobulins and response to therapy. The relative survival rate (the ratio of patient's EMS and EMS in age- and sex-matched general population) was 0.40 in CLL patients and 0.13 in CML patients. Relative survival was more reduced in older CLL patients than in younger ones (0.37 vs 0.47, respectively), whereas relative survival was less reduced in older CML patients than in younger ones (0.18 vs 0.12, respectively). The results show that the age is a significant independent prognostic factor in CLL but not in CML. The difference in the effects of age on prognosis in CLL and CML most probably reflects the fundamental differences in their respective pathogeneses.

Entities:  

Mesh:

Year:  1991        PMID: 1892761      PMCID: PMC1977541          DOI: 10.1038/bjc.1991.303

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  13 in total

1.  TREATMENT OF CHRONIC LEUKEMIAS.

Authors:  E E OSGOOD
Journal:  J Nucl Med       Date:  1964-02       Impact factor: 10.057

2.  A clinical staging system for chronic lymphocytic leukemia: prognostic significance.

Authors:  J L Binet; M Leporrier; G Dighiero; D Charron; P D'Athis; G Vaugier; H M Beral; J C Natali; M Raphael; B Nizet; J Y Follezou
Journal:  Cancer       Date:  1977-08       Impact factor: 6.860

Review 3.  Chronic myelogenous leukemia--past, present, and future.

Authors:  H M Kantarjian; M Talpaz; J U Gutterman
Journal:  Hematol Pathol       Date:  1988

Review 4.  Therapy of chronic myelogenous leukemia: chemotherapy and interferons.

Authors:  M Talpaz; H M Kantarjian; R Kurzrock; J Gutterman
Journal:  Semin Hematol       Date:  1988-01       Impact factor: 3.851

5.  [Prognosis in chronic lymphatic leukemia].

Authors:  A Bernadou; J Bernard; G Bilski-Pasquier; J Bousser
Journal:  Ann Med Interne (Paris)       Date:  1973 Aug-Sep

6.  The pathogenesis of chronic lymphocytic leukemia.

Authors:  D A Galton
Journal:  Can Med Assoc J       Date:  1966-05-07       Impact factor: 8.262

7.  A comparative study of dibromomannitol and busulfan in the treatment of chronic myeloid leukemia. A study of cancer and leukemia group B.

Authors:  R T Silver; R Mick; R Cooper; R R Ellison; R Levy; K Brunner; J M Schwartz; J F Holland
Journal:  Cancer       Date:  1987-10-01       Impact factor: 6.860

8.  Factors influencing the duration of survival of patients with chronic lymphocytic leukemia.

Authors:  D R Boggs; S A Sofferman; M M Wintrobe; G E Cartwright
Journal:  Am J Med       Date:  1966-02       Impact factor: 4.965

9.  Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC Working Party on Leukaemia in Adults.

Authors:  D Catovsky; J Fooks; S Richards
Journal:  Br J Haematol       Date:  1989-06       Impact factor: 6.998

10.  Staging of chronic myeloid leukaemia.

Authors:  S Tura; M Baccarani; G Corbelli
Journal:  Br J Haematol       Date:  1981-01       Impact factor: 6.998

View more
  2 in total

1.  Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-Cll 2017.

Authors:  Branimir Jakšić; Vlatko Pejša; Slobodanka Ostojić-Kolonić; Ika Kardum-Skelin; Sandra Bašić-Kinda; Božena Coha; Velka Gverić-Krečak; Radovan Vrhovac; Ozren Jakšić; Igor Aurer; Jasminka Sinčić-Petričević; Antica Načinović-Duletić; Damir Nemet
Journal:  Acta Clin Croat       Date:  2018-03       Impact factor: 0.932

Review 2.  HOLISTIC APPROACH TO THE IMMUNOBIOLOGY OF AGING (VIEW ON THE TURN OF MILLENIUM).

Authors:  Branko Vitale
Journal:  Acta Clin Croat       Date:  2019-06       Impact factor: 0.780

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.